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Tolvaptan  (TLV),  which  is  an  antagonist  to the  vasopressin  V2  receptor,  was  approved  by  Japanese  author-
ities for  the treatment  of  “volume  overload  in heart failure  when  adequate  response  is not  obtained  with
other  diuretics  (e.g. loop  diuretics)”.  An  82-year-old  female  Japanese  patient  was  admitted  to  our  hos-
pital due  to congestive  heart failure  (CHF)  and  exacerbation  of type 2 chronic  respiratory  failure,  which
improved  with  ventilator  support  and  treatment  with  furosemide;  however,  the  CHF  worsened  again
due  to  anemia  and  undernutrition.  TLV  (7.5  mg/day)  was given.  The  free-water  clearance  value  showed
the  efﬁcacy  of  TLV;  it  was  −0.04  before  and  0.39  six  hours  after  TLV  administration.  The  administration  of
TLV  was  continued  for ﬁve  consecutive  days,  and  the  fractional  excretion  of  sodium  showed  the efﬁcacy
of  furosemide;  it was  1.7%  before  and  5.2%  ﬁve  days  after  TLV  administration.  It  is  known  that  the long-
term  usage  of  loop  diuretics  causes  tolerance  because  it promotes  sodium  re-absorption  through  the
proximal  renal  tubules  by  activating  the renin–angiotensin-aldosterone  system.  A  patient  with  CHF  was
treated  successfully  by  concomitant  administration  of  TLV  with  furosemide.  TLV  worked  both  directly
and  indirectly;  it promoted  free-water  ﬁltration  as its  direct  effect  and  sodium  ﬁltration  as  its  indirect
effect.
<Learning  objective:  Tolvaptan  is  a new  type  drug  for heart  failure  that  promotes  water  diuresis  by
selectively  inhibiting  the  vasopressin  V2  receptors  in collecting  tubules.  Concomitant  use  of  tolvaptan
with  loop  diuretics,  such  as  furosemide,  enhances  the  diuretic  action.  The  mechanism  of  enhanced  diuretic
action  induced  by the concomitant  use  of  tolvaptan  with  loop  diuretics  not  only  promotes  water  diuresis,
ary  
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Tolvaptan (TLV), which is an antagonist to the vasopressin V2
eceptor, was approved by Japanese authorities in December 2010
or the treatment of “volume overload in heart failure when ade-
uate response is not obtained with other diuretics (e.g. loop
iuretics),” and TLV’s efﬁcacy has been acknowledged since then
1]. TLV has a speciﬁc feature of excreting only water without
ncreasing electrolyte excretion due to its effect as an antagonist
o the vasopressin V2 receptor in the renal collecting tubule.
It has been reported that the decrease in urine osmolality
eﬂects the effects of TLV, because the administration of TLV
nduces the excretion of free-water that leads to a decrease in
rine osmolality [2]. However, there are cases that show an
ncrease in urine osmolality after the initial decrease with TLV
∗ Corresponding author. Tel.: +81 3 5632 3111; fax: +81 3 5632 3728.
E-mail address: ynishiza@juntendo.ac.jp (Y. Nishizaki).
878-5409/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2013.07.005function,  but  may  also  enhance  natriuresis  induced  by loop  diuretics.>
anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
administration. It is assumed that this may  involve a mecha-
nism other than free-water excretion because, in such cases, the
increased urine output remains despite the re-increase in urine
osmolality. We  hypothesized that TLV has supplemental effects
to enhance the natriuresis that loop diuretics induce. In order to
prove this mechanism, the following direct and indirect effects
of TLV were retrospectively assessed in a patient with conges-
tive heart failure (CHF) due to severe aortic valve stenosis and cor
pulmonale who  was successfully treated by concomitant admin-
istration of TLV with furosemide. The free-water excretion was
assessed by free-water clearance to evaluate TLV’s direct effect,
and the natriuresis-enhancing action was assessed by fractional
excretion of sodium (FENa) to evaluate TLV’s indirect effect.
Case reportAn 82-year-old woman  was  admitted to a university hospital
emergency department with oxygen desaturation, headache, and
nausea. Blood gas analysis showed hypercapnia. She was diagnosed
vier Ltd. All rights reserved.
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the CHF. The patient recovered to be able to stand with gripping
and was  discharged from hospital on hospital day 171.52 Y. Nishizaki et al. / Journal of 
s having CO2 narcosis and an acute exacerbation of CHF due to
espiratory infection, and she was admitted immediately.
The patient was diagnosed with type 2 chronic respiratory
ailure caused by a restrictive disorder due to old pulmonary
uberculosis and CHF caused by severe aortic valve stenosis and
oderate aortic insufﬁciency. The last echocardiographic exami-
ation showed: aortic valve area 0.82 cm2; left ventricular ejection
raction 0.73; and early diastolic ﬁlling wave/atrial ﬁlling wave ratio
.66. She had been previously admitted to our hospital for CHF and
as treated for it at home after being discharged. Recently, she had
tarted home oxygen therapy under the supervision of her home
octor.
On physical examination at admission, the patient’s height was
37 cm,  and her weight was 29 kg. Her temperature was 37.4 ◦C,
lood pressure 166/95 mmHg, heart rate 100/min (regular), and
pO2 92% (2 L nasal canula). On cardiac auscultation, a Levine 4/6
ystolic murmur was heard. She had no peripheral edema. The ini-
ial blood examination showed: white blood cell count 4300/L,
emoglobin 11.8 g/dL, C-reactive protein 0.4 mg/dL, blood urea
itrogen 25.3 mg/dL, creatinine 0.66 mg/dL, aspartate aminotrans-
erase 20 IU/L, alanine aminotransferase 14 IU/L, Na 134 mEq/L,
 4.5 mEq/L, Cl 90 mEq/L, creatine kinase 33 IU/L, total protein
.5 g/dL, and albumin 3.2 g/dL. The blood gas analysis showed pH
.25, PCO2 87.0 mmHg, PO2 72.4 mmHg, and HCO3− 37.6 mmol/L
2 L nasal cannula). The admission electrocardiogram showed sinus
achycardia with complete right bundle branch block. A chest X-
ay showed cardiomegaly (cardiothoracic ratio 67%) and bilateral
leural effusions.
She was treated for a respiratory infection with antibiotics, but
entilator support became necessary because of respiratory status
eterioration. She was transferred to our hospital on the 14th day
fter admission, because she had been originally under our care.
Weaning from mechanical ventilation was tried. The blood
as analysis values were stable: pH 7.43, pCO2 43.7 mmHg, pO2
7.5 mmHg, and HCO3− 29.1 mmol/L. On hospital day 4, extuba-
ion was attempted, but the patient was re-intubated because her
espiratory and cardiovascular dynamics were unstable. On hos-
ital day 9, a tracheostomy was performed. The CHF was  treated
ith furosemide and spironolactone, and positive end-expiratory
ressure was introduced at night. The results of treatment were
atisfactory, and rehabilitation was started on hospital day 34.
n hospital day 50, percutaneous endoscopic gastrostomy was
erformed, and tube feeding was started because her intake was
nsufﬁcient and her malnutrition might have worsened. Rehabilita-
ion was then continued until hospital discharge, and her activities
f daily living improved. The regimen for the CHF was  furosemide
0 mg/day and spironolactone 50 mg/day, but the CHF deteriorated
ue to anemia (hemoglobin 8.3 g/dL) and undernutrition (albumin
.7 g/dL). Additional treatment for the CHF was necessary because
ystemic edema, cardiomegaly, and bilateral pleural effusions on
hest X-ray (Fig. 1) were observed. TLV was chosen as the additional
reatment for the following reasons: First, worsening systemic
dema was noted on physical examination, and increased pleural
ffusion, advancement of cardiomegaly and increased pleural con-
estion were noted on chest X-ray (see Fig. 1 for chest X-ray). We
urmised that sodium reabsorption and water retention due to the
ctivated renin–angiotensin-aldosterone system were responsible
or this worsening in ﬁndings. Second, we also observed a decrease
n the serum potassium value to as low as 3.6 mEq/L just before
LV administration (when compared with 4.5 mEq/L on admission),
hich also suggested an activated renin–angiotensin-aldosterone
ystem. Third, previous studies have shown that hypoalbuminuria
mpairs delivery of the effective amount of furosemide to its site
f action; protein bound furosemide is delivered to the tubular
ells where it inhibits Na/K/2Cl transporters. Thus, we  also sur-
ised that reduced serum albumin concentration played a role inFig. 1. Chest X-ray before administration of tolvaptan.
the decreased effects of furosemide, because the serum albumin
concentration just before TLV administration was 1.7 g/dl.
TLV administration (7.5 mg/day) was started from hospital day
104. Fig. 2 shows the values of systolic blood pressure, serum
sodium, serum creatinine, urine osmolality, plasma osmolality,
urine output, and body weight, as well as the diuretics administered
to the patient, at the time of the exacerbation of CHF. TLV admin-
istration was continued for ﬁve consecutive days, with an increase
in urine volume and a decrease in body weight. On chest X-ray, the
pleural effusion decreased, and the cardiomegaly improved (Fig. 3).
The systemic edema resolved, and it was  concluded that the treat-
ment of CHF with short-term TLV administration was successful.
We observed an increase in urine osmolality and decrease in serum
sodium at an early stage after TLV discontinuation. Whereas urine
volume gradually decreased, it remained rather constant and was
about 1500 ml  even 1 week after TLV discontinuation. The rehabil-
itation was  then continued steadily without further aggravation ofFig. 2. Systolic blood pressure, serum sodium, serum creatinine, urine osmolality,
plasma osmolality, urine output, body weight, and diuretics administered to the
patient at the time of the exacerbation of congestive heart failure.
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placebo-controlled study of TLV monotherapy compared to furosemide and theFig. 3. Chest X-ray after administration of tolvaptan.
iscussion
A patient with CHF due to severe aortic valve stenosis and cor
ulmonale was successfully treated with the concomitant admin-
stration of TLV with furosemide. The dose of furosemide was  not
ncreased, because furosemide tolerance had already developed
nd because the effects of furosemide were attenuated by hypoal-
uminemia. Because long-term use of loop diuretics promotes
odium re-absorption by the proximal renal tubules through the
ctivation of the renin–angiotensin-aldosterone system [3], there
re reports that loop diuretics may  result in worse outcomes [4,5].
The change of urine osmolality in Fig. 2 shows that it increased
t day two after having decreased at day one despite continued
LV administration. Furthermore, the urine volume that increased
fter the administration of TLV remained without decreasing. These
acts prove that TLV has effects other than its direct effect to
xcrete free-water. A possible mechanism other than excreting
ree-water would be the enhancement of the effects of furosemide.
e also considered the possibility that the effects of furosemide re-
ppeared after the release of kidney congestion by the additional
dministration of TLV. Therefore, we decided to retrospectively
ssess the free-water excretion that is a direct effect of TLV by using
ree-water clearance, and to assess the enhancement of natriuresis
hat may  be an indirect effect of TLV by using FENa.
Free-water clearance is an index of the excreted amount of free-
ater that does not include solutes, and it would be the optimal
arker if we consider that TLV leads to the excretion of water
lone without increased electrolyte excretion. Free-water clear-
nce is calculated according to the formula shown in Appendix,
nd it becomes positive when an aquaretic action takes place. In
nimal experiments, TLV has been proven to increase urine vol-
me  and reduce urine osmolality. The free-water clearance became
ositive, which indicates an increase in free-water excretion, or the
quaretic effect [6,7]. Because the free-water clearance was −0.04
efore TLV administration, 0.39 six hours, 0.89 twenty-four hours,
nd 0.21 ﬁve days after TLV administration, the efﬁcacy of TLV could
e assessed. The FENa showed the efﬁcacy of furosemide; it was
.7% before TLV administration, 0.8% six hours, 1.9% twenty-four
ours, and 5.2% ﬁve days after administration.
[logy Cases 8 (2013) 151–154 153
The value of FENa increased signiﬁcantly on the ﬁfth day of
TLV administration. This indicates that TLV, for some time from
the start of its administration, enhanced the natriuresis induced
by furosemide. We  surmise that TLV enhances the effects of
furosemide. The possible mechanisms, though they are yet to be
clariﬁed, include the alleviation of kidney congestion and/or intesti-
nal edema. It is not clear why  there was  no change (not increased)
in the urine volume despite additional effect of furosemide when
comparing day 1 and day 2 after the administration of TLV but we
surmise that the effects of TLV are enhanced at an advanced stage of
congestion (the beginning of TLV administration). Our hypothesis
requires further investigation in a larger number of patients.
There is a possibility to reduce the dose of loop diuretics in the
treatment for CHF by the concomitant use of TLV, and this possibil-
ity, which is TLV’s enhancing action on the effects of furosemide,
is the most important clinical implication we  obtained through
the present case. The reduction in the dose of loop diuretics can
supposedly suppress facilitation of renin–angiotensin-aldosterone
system, and it may  lead to improvement in the long-term prognosis
of patients with CHF.
Conclusion
A patient with CHF due to severe aortic valve stenosis and cor
pulmonale was successfully treated with the concomitant admin-
istration of TLV with furosemide. To clarify the mechanism of TLV’s
effects, the excretion of free-water was assessed using free-water
clearance for TLV’s direct effect, while the natriuresis was  evalu-
ated using FENa for TLV’s possible indirect effect. This retrospective
examination of this case suggests that TLV enhances the effects of
furosemide.
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Appendix
Formula for free-water clearance [8]
Free-water clearance = V − Cosm = V − (Uosm × V)/(Posm)
V  = urine ﬂow rate
Cosm = osmolar clearance
Uosm = urine osmolarity
Posm = plasma osmolarity
When free-water clearance is positive, excess water is being excreted by the
kidney; when free-water clearance is negative, excess solutes are being
removed from the blood by the kidneys, and water is being conserved.
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